The lectin pathway of the complement system may be involved in the pathogenesis of pre-eclampsia. We aimed to investigate changes in serum concentrations of a broad range of lectin pathway proteins during normal pregnancy and their association with pre-eclampsia, placental infarctions and intrauterine growth restriction (IUGR).
| INTRODUC TI ON
pre-eclampsia affects approximately 5% of all pregnancies worldwide 1 and is a major cause of maternal and perinatal morbidity and mortality. 2 The condition is characterized by new-onset hypertension after the 20th gestational week and proteinuria and is associated with potentially life-threatening maternal organ dysfunction as well as intrauterine growth restriction (IUGR) and preterm birth.
3,4
The cause of pre-eclampsia is debated, but an abnormal trophoblast invasion and impaired remodelling of uterine spiral arteries are considered the main pathogenetic factors. 5 Furthermore, pre-eclampsia is characterized by enhanced apoptotic 6 and inflammatory changes 7 in the placenta as well as excess placental infarction.
8
A dysregulated maternal immune response is regarded a key factor in the abnormal placental establishment in early pregnancy, 9 and the complement system has been suggested as an important contributor, 10 as signs of systemic increased complement activation in pre-eclampsia with increased classical and terminal pathway activity have been described. 11 The complement system is part of the innate immune system, providing a first line defence against infection.
The system is also an intimate part of the recognition and clearing of altered-self structures, for example, as may occur through pregnancies. 12, 13 Complement activation generates inflammatory mediators which facilitate a crucial danger signal to surrounding cells and migrating leucocytes. 14 The lectin pathway, which is the most recently described complement activation pathway, has gained much interest in the development of pre-eclampsia and IUGR. [15] [16] [17] [18] [19] [20] [21] The lectin pathway consists of the pattern recognition molecules mannose-binding lectin (MBL), ficolins (H-, L-and M-) and collectins liver-1 (CL-L1) and kidney-1 (CL-K1), together with the MBL-associated serine protease (MASP)-1, MASP-2 and MASP-3 and the regulatory MBL-associated proteins of 19 kDa (MAp19) and 44 kDa (MAp44). 22 MBL may be directly involved in the impairment of spiral artery remodelling and trophoblast invasion in early pregnancy. 15, 16 Furthermore, the pattern recognition molecules recognize not only pathogens but also necrotic or apoptotic cells. 12, 13 Thus, pattern recognition and subsequent complement activation in the pre-eclampsia-affected placenta may contribute to inflammation and placental insufficiency later in pregnancy. Finally, MASP-1 and MASP-2 enhance prothrombin activation, fibrin formation and clot stabilization in vitro. [23] [24] [25] This may aggravate placental infarction and further impair placental function.
Increased circulating MBL concentrations have been reported for pregnant women with pre-eclampsia compared with normotensive pregnant women. 17, 18 One study found an association between high MBL serum concentration and impaired placental perfusion.
18
Others found that MBL2 genotypes normally causing high MBL serum concentrations were more prevalent in women with pre-eclampsia than in healthy pregnant women. 19, 20 These findings indicate a protective effect of low serum MBL on pre-eclampsia risk.
However, this was contradicted by a study which found a higher prevalence of MBL2 genotypes associated with low MBL serum concentrations in pre-eclampsia than in normotensive pregnancy.
26
Other studies reported no differences in MBL serum concentrations [27] [28] [29] or MBL2 genotype distribution 30 between women with pre-eclampsia and normotensive pregnant women.
Concerning other lectin pathway proteins, two studies reported lower serum concentrations of H-and L-ficolin in pre-eclampsia than in normotensive pregnancy. 21, 27 Finally, a recent study reported that several MASP1 polymorphisms which may impair MASP-1 synthesis were associated with a higher risk of pre-eclampsia. 31 Serum concentrations of MASP-1, MASP-2 or MASP-3, M-ficolin or CL-L1/CL-K1 have not been investigated previously in women with pre-eclampsia. Thus, the association between MBL and pre-eclampsia is still not fully elucidated, while the role of other lectin pathway proteins in pre-eclampsia is not well investigated.
The present study aimed to investigate changes in serum concentrations of lectin pathway proteins during normal pregnancy and their possible association with the development of pre-eclampsia, placental infarctions and IUGR.
| MATERIAL S AND ME THODS

| Design and study population
The present study included two groups of pregnant women: (a) normotensive pregnant women and (b) pregnant women with pre-eclampsia. The women were prospectively enrolled at the Table 1 ). Sixty-one women were included, with serum available from 54 women for the present study.
All participants gave written informed consent to be included in the original study, which was carried out in accordance with the Helsinki All health care data were fully anonymized for the present study.
Lectin pathway protein concentrations in healthy, non-pregnant female blood donors (n = 149), enrolled from the blood bank at the Department of Clinical Immunology, Aarhus University Hospital, Denmark, have previously been described by our group. Gestational diabetes mellitus 0 2
| Clinical outcomes
Betamethasone before birth 0 (0) 23 (43) pre-eclampsia in previous pregnancy Data not available 12 (24) 1 (2) Data are presented as either mean ± standard deviation, median (interquartile range) or n (%). GA, gestational age (wk); HELLP, haemolysis, elevated liver enzymes, low platelets; IUGR, intrauterine growth restriction; LMWH, low molecular weight heparin; VTE, venous thromboembolism. a Indication for LMWH prophylaxis: known thrombophilia, n = 2, other indications (immobilization, previous obstetric complication), n = 2. b Data on venous thromboembolism were obtained from medical records. Participants were followed until 6 wk after delivery.
TA B L E 1 Clinical and demographic characteristics on normotensive pregnant women and women with pre-eclampsia
Infarction of up to 5% of the placental parenchyma is considered a normal finding in full-term healthy pregnancies 4 ; therefore, we defined ≥10% infarction of the total placental parenchyma as clinically significant.
Data on placental fibrin deposition and inflammation were available, but since the number of events was low (fibrin deposition, n = 3; inflammation, n = 4), statistical analysis was not performed for these variables.
| Lectin pathway protein analysis
Blood samples were drawn in 5 MASP-1 was analysed as previously described by our group, 33 except that plates were coated with murine anti-MASP-1 antibodies (clone 1H1G6, Genscript, lot no A217100014) instead of the previously used antibody. For H-ficolin, acetylated bovine serum albumin was used as the capturing agent as described by Hein et al. 41 The wells were coated with 10 μg/mL acetylated bovine serum albumin (Sigma ® B2518, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) diluted in coating buffer (0.1 mol/L sodium bicarbonate, pH 9.6 with 0.09% (w/v) sodium azide). Standards, controls and samples were diluted in Tris-buffered saline with 0.05% Tween-20, 5 mmol/L CaCl 2 and 1 mg/mL human serum albumin, and in-house biotinylated mouse anti-human H-ficolin (clone 4H5, HyCult ® Biotechnology, Uden, the Netherlands, cat# HM2089b) was used as detecting antibody as previously described by our group. 42 Each microtiter plate contained three quality controls. All standards, controls and samples were added in duplicate, and a coefficient of variation of 15% was accepted. The person performing the analysis (JBL) was blinded to placental pathology and IUGR status at the time of analysis.
| Statistics
Data were visually assessed for Gaussian distribution using quan- 
| RE SULTS
| Study population
In total, serum samples were available from 51 normotensive pregnant women, of which 37 had a post-delivery sample. For women with pre-eclampsia, serum samples were available for 54 women, of which 51 had a post-delivery sample. Demographic and clinical characteristics are shown in Table 1 .
| Lectin pathway protein serum concentrations
Lectin pathway protein concentrations in normotensive pregnant women and women with pre-eclampsia at all sampling times are displayed in Table S1 . Lectin pathway protein concentrations (IQR) in healthy non-pregnant women are displayed as dotted lines in Figures   1 and 2. 3.3 | Changes during and after pregnancy
| Normotensive pregnant women
All lectin pathway proteins except M-ficolin and MASP-3 increased significantly during pregnancy in the normotensive group (Figure 1 ). The median increase from GA 16 to GA 37 ranged from 11% (IQR: 0%-23%) for CL-L1 to 39% (IQR: 27%-51%) for MAp19 (all P < 0.0001). For H-ficolin, the increase occurred primarily from GA 16 to GA 33 (median increase 19% (IQR: 11%-25%), P < 0.0001) with a drop from GA 33 to GA 37. A decrease from GA 37 to after delivery was observed for almost all proteins, ranging from 15% (IQR: 1%-24%) for H-ficolin to 54% (IQR: 48%-76%) for MBL (all P < 0.001). An exception was MASP-3, which displayed a 30% (IQR: 8%-44%) increase from GA 37 to after delivery (P < 0.001).
| Women with pre-eclampsia
In the pre-eclampsia group (Figure 2 ), a similar pattern was observed as for the normotensive group with significant decreases in most protein concentrations after delivery, ranging from 12% (IQR: −21% to 31%) for M-ficolin to 58% (IQR: 48%-62%) for MASP-1.
Exceptions were H-ficolin and MASP-3 which showed a median increase after delivery of 30% (IQR: 15%-65%) for H-ficolin and 53%
(IQR: 34%-81%) for MASP-3, both P < 0.0001. MASP-2 did not change significantly (P = 0.22).
We also examined the influence of pre-eclampsia severity on the lectin pathway and observed no difference in lectin pathway protein concentrations between women with mild or moderate pre-eclampsia (n = 11) and women with severe pre-eclampsia or HELLP (n = 43) 
| D ISCUSS I ON
We showed that lectin pathway protein concentrations increased during pregnancy and decreased after delivery. Exceptions were Our results demonstrate that lectin pathway protein concentrations generally increase during normal pregnancy and decrease after delivery, to a level similar to healthy non-pregnant women. 33 An exception was MASP-3 which increased after delivery. Our results are supported by van de Geijn et al 43 who found an approximate increase of 50% in serum MBL during normal pregnancy and a decline again 6 weeks after delivery. Consecutive serum concentrations of MASP-1, MASP-2 and MASP-3 and MAp19 and MAp44 during pregnancy have not been described previously. We were not able to follow women with pre-eclampsia at several time points during pregnancy, but we found a similar pattern of higher concentrations in late pregnancy and a decline after delivery, except for MASP-3 and H-ficolin, which were low in late pregnancy and increased after delivery. Our findings support an upregulation of innate immunity during pregnancy, with a return towards pre-pregnancy conditions when the maternal circulation is no longer exposed to the placenta.
43
We observed lower concentrations of H-ficolin, M-ficolin and MASP-3 in women with pre-eclampsia than in normotensive pregnant women. This supports previous findings of lower H-ficolin levels in pregnancies complicated by pre-eclampsia as compared with normotensive pregnancies. 21 ,27 Yet, M-ficolin and MASP-3 have not been investigated previously in pregnancies complicated by pre-eclampsia, whereas MBL is extensively investigated in pre-eclampsia. [17] [18] [19] [20] 28, 29 Some previous studies described increased MBL concentrations in pre-eclampsia compared with normotensive pregnancy 17,18 while others found no difference. 28, 29 Our results support the latter. These discrepant findings may be due to differences in the employed pre-eclampsia criteria, the laboratory assays used or the statistical power across studies.
Excess placental infarction and IUGR were associated with lower MASP-3 and H-ficolin concentrations, both in the overall study C4d deposition in placentae from women with pre-eclampsia 51, 52 have also been described. However, H-ficolin shows some diurnal variation 33 and is subjective to changes due to infection and inflammatory conditions, 57 which limits its clinical usefulness.
A strength of the present study was the longitudinal sample collection which allowed us to assess lectin pathway proteins both during pregnancy and after delivery in a well-described study population. We assessed a broad range of lectin pathway proteins, some of which have not previously been investigated in normal pregnancy or in pre-eclampsia. We ensured a high validity of the pre-eclampsia diagnosis through verification by two independent obstetricians. Moreover, experienced perinatal pathologists performed the placental pathology investigations. However, some limitations should be considered. Two women with pre-eclampsia had gestational diabetes mellitus, which could influence lectin pathway protein serum concentrations, as described for non-pregnant diabetic subjects. 58, 59 However, since this was a low proportion of the entire cohort, we assumed that it would not influence our results. Four women received low molecular weight heparin during pregnancy, but we have previously shown that low molecular weight heparin in prophylactic doses does not influence lectin pathway protein plasma concentrations. 60 GA was similar but not identical in the normotensive group and the pre-eclampsia group, and we cannot exclude a possible influence on our results.
Additionally, for the pre-eclampsia group, the timing of blood sample collection after delivery varied widely. We cannot exclude that glucocorticoid treatment could have influenced our results. The effect of glucocorticoid treatment on MASP-3 plasma levels is not well investigated; one study found an upregulating effect of dexamethasone on the MASP1/3 gene in vitro. 61 The time from blood sampling to analysis was long. Nevertheless, lectin pathway proteins are stable in serum for several years at −80°C (unpublished results from our laboratory), but we cannot rule out that some evaporation may have occurred, possibly resulting in higher absolute protein concentrations. However, this increased storage time was non-differential across the groups; thus, we consider it unlikely to have influenced the main conclusion of our findings.
Differences in lectin pathway proteins between early-and lateonset pre-eclampsia could have been of interest; however, the women were classified according to pre-eclampsia severity and not onset time; thus, it was not possible to investigate this issue.
Finally, our sample size was moderate; thus, our study may underestimate associations between placental infarction or IUGR and lectin pathway proteins.
In conclusion, we found that H-ficolin and MASP-3 serum concentrations were lower in the 3rd trimester than after delivery and were lower in women with pre-eclampsia than in normotensive preg- 
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